Targeting the Wnt signaling pathway for the development of novel therapies for osteoporosis

References

• Consensus Development Conference on Osteoporosis. Am. J. Med.95(5A), 1S–78S (1993).
   PubMedGoogle Scholar
• Cummings SR, Martin JS, McClung MR et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med.361(8), 756–765 (2009).
   PubMed Web of Science ®Google Scholar
• Bone HG, McClung MR, Roux C et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J. Bone Miner. Res.25(5), 937–947 (2010).
   PubMed Web of Science ®Google Scholar
• McClung M, Bone H, Dempster D et al.Phase 3 fracture trial of odanacatib for osteoporosis- study design. Bone47, S217–S218 (2010).
   Google Scholar
• Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Ann. Rev. Cell Dev. Bio20, 781–810 (2004).
   PubMed Web of Science ®Google Scholar
• Gordon MD, Nusse R. Wnt Signaling: multiple pathways, multiple receptors, and multiple transcription factors. J. Biol. Chem.281(32), 22429–22433 (2006).
   PubMed Web of Science ®Google Scholar
• Carmon KS, Loose DS. Development of a bioassay for detection of Wnt-binding affinities for individual frizzled receptors. Anal. Biochem.401(2), 288–294 (2010).
   PubMedGoogle Scholar
• Cavallo RA, Cox RT, Moline MM et al. Drosophila Tcf and Groucho interact to repress Wingless signaling activity. Nature395(6702), 604–608 (1998).
   PubMed Web of Science ®Google Scholar
• Hecht A, Vleminckx K, Stemmler MP, van Roy F. The p300/CBP acetyltransferases function as transcriptional coactivators of β-catenin in vertebrates. EMBO J.19(8), 1839–1850 (2000).
   PubMed Web of Science ®Google Scholar
• Gaur T, Lengner CJ, Hovhannisyan H et al. Canonical Wnt signaling promotes osteogenesis by directly stimulating Runx-2 gene expression. J. Bio Chem.280(39), 33132–33140 (2005).
   PubMed Web of Science ®Google Scholar
• Glass DA 2nd, Bialek P, Ahn JD et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast formation. Dev. Cell8(5), 751–764 (2005).
   PubMed Web of Science ®Google Scholar
• Gong Y, Slee RB, Fukai N et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell107(4), 513–523 (2001).
   PubMed Web of Science ®Google Scholar
• Boyden LM, Mao J, Belsky J et al. High bone density due to a mutation in LDL-receptor-related protein 5. N. Engl. J. Med.346(20), 1513–1521 (2002).
   PubMed Web of Science ®Google Scholar
• Little RD, Carulli JP, Del Mastro RG et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am. J. Hum. Genet.70(1), 11–19 (2002).
   PubMed Web of Science ®Google Scholar
• Ohazama A, Johnson EB, Ota MS et al. Lrp4 modulates extracellular integration of cell signaling pathways in development. PLoS ONE3(12), e4092 (2008).
   PubMedGoogle Scholar
• Choi HY, Dieckmann M, Herz J, Niemeier A. Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo. PLoS ONE4(110), e7930 (2009).
   PubMed Web of Science ®Google Scholar
• Styrkarsdottir U, Halldorsson BV, Gretarsdottir S et al. New sequence variants associated with bone mineral density. Nat. Genet.41(1), 15–7 (2009).
   PubMed Web of Science ®Google Scholar
• Rivadeneira F, Styrkársdottir U, Estrada K et al. Genetic Factors for Osteoporosis (GEFOS) Consortium. Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat. Genet.41(11), 1199–1206 (2009).
   PubMed Web of Science ®Google Scholar
• Balemans W, Ebeling M, Patel N et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum. Mol. Genet.10(5), 537–43 (2001).
   PubMed Web of Science ®Google Scholar
• Staehling-Hampton K, Proll S, Paeper BW et al. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am. J. Med. Genet.110(2), 144–152 (2002).
   PubMed Web of Science ®Google Scholar
• Veeman MT, Axelrod JD, Moon RT. A second canon. Functions and mechanisms of β-catenin-independent Wnt signaling. Dev. Cell5(3), 367–377 (2003).
   PubMed Web of Science ®Google Scholar
• Yoda A, Oishi I, Minami Y. Expression and function of the Ror-family receptor tyrosine kinases during development: lessons from genetic analyses of nematodes, mice, and humans. J. Recept. Signal. Transduct. Res.23(1), 1–15 (2003).
   PubMed Web of Science ®Google Scholar
• Tu X, Joeng KS, Nakayama KI et al. Noncanonical Wnt signaling through G protein-linked PKCδ activation promotes bone formation. Dev. Cell12(1), 113–127 (2007).
   PubMed Web of Science ®Google Scholar
• Yu HC, Wu TC, Chen MR, Liu SW, Chen JH, Lin KM. Mechanical stretching induces osteoprotegerin in differentiating C2C12 precursor cells through noncanonical Wnt pathways. J. Bone Miner. Res.25(5), 1128–1137 (2010).
   Google Scholar
• Arnsdorf EJ, Tummala P, Jacobs CR. Non-canonical Wnt signaling and N-cadherin related β-catenin signaling play a role in mechanically induced osteogenic cell fate. PLoS ONE4(4), e5388 (2009).
   PubMed Web of Science ®Google Scholar
• Caverzasio J. Non-canonical Wnt signaling: what is its role in bone? IBMS Bonekey6(3), 107–115 (2009).
   Google Scholar
• Liu Y, Bodine PV, Billiard J. Ror2, a novel modulator of osteogenesis. J. Musculoskelet. Neuronal Interact.7(4), 323–324 (2007).
   Google Scholar
• Poole KE, van Bezooijen RL, Loveridge N et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J.19 (13), 1842–1844 (2005).
   PubMed Web of Science ®Google Scholar
• Winkler DG, Sutherland MK, Geoghegan JC et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J.22(23), 6267–6276 (2003).
   PubMed Web of Science ®Google Scholar
• van Bezooijen RL, Papapoulos SE, Löwik CW. Bone morphogenetic proteins and their antagonists: the sclerostin paradigm. J. Endocrinol. Invest.28(8 Suppl.), 15–17 (2005).
   Google Scholar
• ten Dijke P, Krause C, de Gorter DJ, Löwik CW, van Bezooijen RL. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. J. Bone Joint Surg. Am.90(Suppl. 1), 31–35 (2008).
   PubMed Web of Science ®Google Scholar
• van Bezooijen RL, Svensson JP, Eefting D et al. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J. Bone Miner. Res.22(1), 19–28 (2007).
   PubMed Web of Science ®Google Scholar
• Semënov M, Tamai K, He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J. Biol. Chem.280(29), 26770–26775 (2005).
   PubMed Web of Science ®Google Scholar
• Li X, Zhang Y, Kang H et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J. Biol. Chem.280(20), 19883–19887 (2005).
   PubMed Web of Science ®Google Scholar
• Semenov MV, He X. LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST. J. Biol. Chem.281(50), 38276–38284 (2006).
   PubMed Web of Science ®Google Scholar
• Li X, Ominsky MS, Niu QT et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J. Bone Miner. Res.23(6), 860–869 (2008).
   PubMed Web of Science ®Google Scholar
• Li X, Ominsky MS, Warmington KS et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J. Bone Miner. Res.24(4), 578–588 (2009).
   PubMed Web of Science ®Google Scholar
• Bell KL, Loveridge N, Power J, Garrahan N, Meggitt BF, Reeve J. Regional differences in cortical porosity in the fractured femoral neck. Bone24 (1), 57–64 (1999).
   PubMed Web of Science ®Google Scholar
• Wachter NJ, Krischak GD, Mentzel M et al. Correlation of bone mineral density with strength and microstructural parameters of cortical bone in vitro. Bone31(1), 90–95 (2002).
   PubMed Web of Science ®Google Scholar
• Ominsky M, Vlasseros F, Jolette J et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J. Bone Miner. Res.25(5), 948–959 (2010).
   PubMed Web of Science ®Google Scholar
• Ominsky M, Samadfam R, Jolette J et al. Sclerostin monoclonal antibody stimulates bone formation and improves the strength and density of the fracture callus and lumbar spine in a primate fibular osteotomy model. Presented at: 31st Annual Meeting of the American Society for Bone and Mineral Research. Denver, CO, USA, 11–15 September 2009.
   Google Scholar
• Eddleston A, Marenzana M, Moore AR et al. A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis. J. Bone Miner. Res.24(10), 1662–1671 (2009).
   PubMed Web of Science ®Google Scholar
• Li X, Warmington K, Niu Q et al. Increased bone formation and bone mass by sclerostin antibody was not blunted by pretreatment with alendronate in ovariectomized rats with established osteopenia. Presented at: 31st Annual Meeting of the American Society for Bone and Mineral Research. Denver, CO, USA, 11–15 September 2009.
   Google Scholar
• Li X, Niu Q, Warmington K et al. Increased modeling-based bone formation by sclerostin antibody was not altered by co-treatment with alendronate in ovariectomized rats. Presented at: 31st Annual Meeting of the American Society for Bone and Mineral Research. Denver, CO, USA, 11–15 September 2009.
   Google Scholar
• Padhi D, Graham J, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomised study of AMG 785, a sclerostin monoclonal antibody. J. Bone Miner. Res. DOI: 10.1002/jbmr.173 (2010) (Epub ahead of print).
   Google Scholar
• Gardner JC, van Bezooijen RL, Mervis B et al. Bone mineral density in sclerosteosis; affected individuals and gene carriers. J. Clin. Endocrinol. Metab.90 (12), 6392–6395 (2005).
   PubMed Web of Science ®Google Scholar
• Compston JE. Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure. Bone40(6), 1447–1452 (2007).
   PubMed Web of Science ®Google Scholar
• Ma YL, Zeng Q, Donley DW et al. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J. Bone Miner. Res.21(6), 855–864 (2006).
   PubMed Web of Science ®Google Scholar
• Lindsay R, Cosman F, Zhou H et al. A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J. Bone Miner. Res.21(3), 366–373 (2006).
   PubMed Web of Science ®Google Scholar
• Krupnik VE, Sharp JD, Jiang C et al. Functional and structural diversity of the human Dickkopf gene family. Gene238(2), 301–313 (1999).
   PubMed Web of Science ®Google Scholar
• Mao B, Wu W, Davidson G et al. Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signaling. Nature417(6819), 664–667 (2002).
   PubMed Web of Science ®Google Scholar
• Semënov MV, Tamai K, Brott BK, Kühl M, Sokol S, He X. Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6. Curr. Biol.11(12), 951–961 (2001).
   PubMed Web of Science ®Google Scholar
• Li X, Liu P, Liu W et al. Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation. Nat. Genet.37(9), 945–952 (2005).
   PubMed Web of Science ®Google Scholar
• Van der Horst G, Van der Werf SM, Farih-Sips H, Van Bezooijen RL, Lowik CW, Karperien M. Downregulation of Wnt signaling by increased expression of Dickkopf-1 and-2 is a prerequisite for late-stage osteoblast differentiation of KS483 cells. J. Bone Miner. Res.20(10), 1867–1877 (2005).
   PubMed Web of Science ®Google Scholar
• Mukhipadhyay M, Shtrom S, Rodriguez-Esteban C et al. Dickkopf1 is required for embryonic head induction and limb morphogenesis in the mouse. Dev. Cell1(3), 423–434 (2001).
   Google Scholar
• Morvan F, Boulukos K, Clément-Lacroix P et al. Deletion of a single allele of the Dkk-1 gene leads to an increase in bone formation and bone mass. J. Bone Miner. Res.21(6), 934–945 (2006).
   PubMed Web of Science ®Google Scholar
• Li J, Sarosi I, Cattley RC et al. Dkk-1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone39(4), 754–766 (2006).
   PubMed Web of Science ®Google Scholar
• MacDonald BT, Joiner DM, Oyserman SM et al. Bone mass is inversely proportional to Dkk-1 levels in mice. Bone41(3), 331–339 (2007).
   PubMed Web of Science ®Google Scholar
• Wang FS, Ko JY, Lin CL, Wu HL, Ke HJ, Tai PJ. Knocking down dickkopf-1 alleviates estrogen deficiency induction of bone loss. A histomorphological study in ovariectomized rats. Bone40(2), 485–492 (2007).
   PubMedGoogle Scholar
• Glantsching H, Hampton R, Wei N et al. Fully human anti-DKK-1 antibodies increase bone formation and resolve osteopenia in mouse models of estrogen-deficiency induced bone loss. Presented at: 30th Annual meeting of the American Society of Bone and Mineral Research. Montreal, Quebec, Canada, 12–16 September 2008.
   Google Scholar
• Wang FS, Ko JY, Yeh DW, Ke HC, Wu HL. Modulation of Dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss. Endocrinology149(4), 1793–1801 (2008).
   PubMed Web of Science ®Google Scholar
• Hoeppner LH, Secreto FJ, Westendorf JJ. Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther. Targets13(4), 485–496 (2009).
   PubMed Web of Science ®Google Scholar
• Giuliani N, Morandi F, Tagliaferri S et al. Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment. Cancer Res.67(16), 7665–7674 (2007).
   PubMed Web of Science ®Google Scholar
• Qiang YW, Chen Y, Stephens O et al. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood112(1), 96–207 (2008).
   Google Scholar
• Diarra D, Stolina M, Polzer K et al. Dickkopf-1 is a master regulator of joint remodeling. Nat. Med.13(2), 156–163 (2007).
   PubMed Web of Science ®Google Scholar
• Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD Jr. Antibody-based inhibition of DKK-1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood109(5), 2106–2111 (2007).
   PubMed Web of Science ®Google Scholar
• Heath DJ, Chantry AD, Buckle CH et al. Inhibiting Dickkopf-1 (Dkk-1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J. Bone Miner. Res.24(3), 425–436 (2009).
   PubMed Web of Science ®Google Scholar
• Kawano Y, Kypta R. Secreted antagonists of the Wnt signaling pathway. J. Cell Sci.116(Pt 13), 2627–2634 (2003).
   PubMed Web of Science ®Google Scholar
• Bodine PV, Billiard J, Moran RA et al. The Wnt antagonist secreted frizzled-related protein-1 controls osteoblast and osteocyte apoptosis. Cell. Biochem.96(6), 1212–1230 (2005).
   PubMed Web of Science ®Google Scholar
• Wang FS, Lin CL, Chen YJ et al. Secreted frizzled-related protein 1 modulates glucocorticoid attenuation of osteogenic activities and bone mass. Endocrinology146(5), 2415–2423 (2005).
   PubMed Web of Science ®Google Scholar
• Bodine PV, Zhao W, Kharode YP et al. The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol. Endocrinol.18(5), 1222–1237 (2004).
   PubMed Web of Science ®Google Scholar
• Bodine PV, Seestaller-Wehr L, Kharode YP, Bex FJ, Komm BS. Bone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted frizzled-related protein-1. J. Cell Physiol.210(2), 352–357 (2007).
   PubMed Web of Science ®Google Scholar
• Lories RJ, Peeters J, Bakker A et al. Articular cartilage and biomechanical properties of the long bones in Frzb-knockout mice. Arthritis Rheum.56(12), 4095–4103 (2007).
   PubMedGoogle Scholar
• Bodine PV, Stauffer B, Ponce-de-Leon H et al. A small molecule inhibitor of the Wnt antagonist secreted frizzled-related protein-1 stimulates bone formation. Bone44(6), 1063–1068 (2009).
   PubMed Web of Science ®Google Scholar
• Gopalsamy A, Shi M, Stauffer B et al. Identification of diarylsulfone sulfonamides as secreted frizzled related protein-1 (sFRP-1) inhibitors. J. Med. Chem.51(24), 7670–7672 (2008).
   PubMedGoogle Scholar
• Shi M, Stauffer B, Bhat R et al. Identification of iminooxothiazolidines as secreted frizzled related protein-1 inhibitors. Bioorg. Med. Chem. Lett.19(22), 6337–6339 (2009).
   Google Scholar
• Moore WJ, Kern JC, Bhat R et al. Modulation of Wnt signaling through inhibition of secreted frizzled-related protein 1 (sFRP-1) with N-substituted piperidinyl diphenylsulfonyl sulfonamides. J. Med. Chem.52(1), 105–116 (2009).
   PubMedGoogle Scholar
• Li CH, Amar S. Role of secreted frizzled-related protein 1 (SFRP1) in wound healing. J. Dent. Res.85(4), 374–378 (2006).
   Google Scholar
• Kumar S, Leontovich A, Coenen MJ, Bahn RS. Gene expression profiling of orbital adipose tissue from patients with Graves’ ophthalmopathy: a potential role for secreted frizzled-related protein-1 in orbital adipogenesis. J. Clin. Endocr. Metab.90(8), 4730–4735 (2005).
   PubMedGoogle Scholar
• Wang WH, McNatt LG, Pang IH et al. Increased expression of the WNT antagonist sFRP-1 in glaucoma elevates intraocular pressure. J. Clin. Invest.118(3), 1056–1064 (2008).
   PubMed Web of Science ®Google Scholar
• Harwood AJ. Regulation of GSK-3: a cellular multiprocessor. Cell105(7), 821–824 (2001).
   PubMed Web of Science ®Google Scholar
• Cohen P. The Croonian Lecture. Identification of a protein kinase cascade of major importance in insulin signal transduction. Philos. Trans. R. Soc. Lond. B Biol. Sci.354(1382), 485–495 (1999).
   PubMed Web of Science ®Google Scholar
• Dale TC. Signal transduction by the Wnt family of ligands. Biochem. J.329(2), 209–223 (1998).
   PubMed Web of Science ®Google Scholar
• Zeng X, Tamai K, Doble B et al. A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation. Nature438(7069), 873–877 (2005).
   PubMed Web of Science ®Google Scholar
• Kapadia RM, Guntur AR, Reinhold MI, Naski MC. Glycogen synthase kinase 3 controls endochondral bone development: contribution of fibroblast growth factor 18. Dev. Biol.285(2), 496–507 (2005).
   Google Scholar
• Yun SI, Yoon HY, Chung YS. Glycogen synthase kinase-3β regulates etoposide-induced apoptosis via Bcl-2 mediated caspase-3 activation in C3H10T1/2 cells. Apoptosis14(6), 771–777 (2009).
   PubMed Web of Science ®Google Scholar
• Hoeflich KP, Luo J, Rubie EA et al. Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation. Nature406(6791), 86–90 (2000).
   PubMed Web of Science ®Google Scholar
• Wilting I, de Vries F, Thio BM et al. Lithium use and the risk of fractures. Bone40(5), 1252–1258 (2007).
   PubMedGoogle Scholar
• Kugimiya F, Kawaguchi H, Ohba S et al. Gsk-3 β controls osteogenesis through regulating Runx2 activity. PLoS ONE2(9), e837 (2007).
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Reduced relative risk of fractures among users of lithium. Calcif. Tissue Int.77(1), 1–8 (2005).
   PubMed Web of Science ®Google Scholar
• Eren Y, Yyldyz M, Civi Y, Gundodar D, Ozcankaya R. The effects of lithium treatment on bone mineral density of bipolar patients. Neurol. Psychiatr. Brain Res.13(4), 175–180 (2006).
   Google Scholar
• Pickart CM. Back to the future with ubiquitin. Cell116(2), 181–190 (2004).
   PubMedGoogle Scholar
• Garrett IR, Chen D, Gutierrez G et al. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J. Clin. Invest.111(11), 1771–1782 (2003).
   PubMed Web of Science ®Google Scholar
• Terpos E, Heath DJ, Rahemtulla A et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br. J. Haematol.135(5), 688–692 (2006).
   PubMed Web of Science ®Google Scholar
• Heider U, Kaiser M, Müller C et al. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur. J. Haematol.77(3), 233–238 (2006).
   PubMed Web of Science ®Google Scholar
• Terpos E, Sezer O, Croucher P, Dimopoulos MA. Myeloma bone disease and proteasome inhibition therapies. Blood110(4), 1098–1104 (2007).
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Raje N, Schoonmaker JA et al. Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J. Clin. Invest.118(2), 491–504 (2008).
   PubMed Web of Science ®Google Scholar
• Giuliani N, Morandi F, Tagliaferri S et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood110(1), 334–338 (2007).
   PubMed Web of Science ®Google Scholar
• von Metzler I, Krebbel H, Hecht M et al. Bortezomib inhibits human osteoclastogenesis. Leukemia21(9), 2025–2034 (2007).
   PubMed Web of Science ®Google Scholar
• Ang E, Pavlos NJ, Rea SL et al. Proteasome inhibitors impair RANKL-induced NF-κB activity in osteoclast-like cells via disruption of p62, TRAF6, CYLD, and IkBα signaling cascades. J. Cell Physiol.220(2), 450–459 (2009).
   PubMed Web of Science ®Google Scholar
• Di Gennaro E, Bruzzese F, Caraglia M, Abruzzese A, Budillon A. Acetylation of proteins as novel target for antitumor therapy: review article. Amino Acids26(4), 435–441 (2004).
   PubMed Web of Science ®Google Scholar
• Qiang YW, Hu B, Chen Y et al. Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling. Blood113(18), 4319–4330 (2009).
   PubMed Web of Science ®Google Scholar
• Oyajobi BO, Garrett IR, Gupta A et al. Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease. Br. J. Haematol.139(3), 434–438 (2007).
   PubMed Web of Science ®Google Scholar
• Pennisi A, Li X, Ling W, Khan S, Zangari M, Yaccoby S. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous bones in vivo. Am. J. Hematol.84(1), 6–14 (2009).
   PubMed Web of Science ®Google Scholar
• Marks PA, Dokmanovic M. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig. Drugs14(12), 1497–1511 (2005).
   PubMed Web of Science ®Google Scholar
• Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat. Rev.5(9), 769–7845 (2006).
   Google Scholar
• Bordonaro M, Lazarova DL, Sartorelli AC. The activation of β-catenin by Wnt signaling mediates the effects of histone deacetylase inhibitors. Exp. Cell Res.313(8), 1652–1666 (2007).
   PubMed Web of Science ®Google Scholar
• Yadav VK, Ryu JH, Suda N et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell135(5), 825–833 (2008).
   PubMed Web of Science ®Google Scholar
• Bliziotes M, Eshleman AJ, Zhang XW, Wiren KM. Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake. Bone29(5), 477–486 (2001).
   PubMed Web of Science ®Google Scholar
• Westbroek I, van der Plas A, de Rooij KE, Klein-Nulend J, Nijweide PJ. Expression of serotonin receptors in bone J. Biol. Chem.276(31), 28961–28968 (2001).
   PubMed Web of Science ®Google Scholar
• Warden SJ, Nelson IR, Fuchs RK, Bliziotes MM, Turner CH. Serotonin (5-hydroxytryptamine) transporter inhibition causes bone loss in adult mice independently of estrogen deficiency. Menopause15(6), 1176–1183 (2008).
   PubMed Web of Science ®Google Scholar
• Haney EM, Warden SJ, Bliziotes MM. Effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening, prevention and management? Bone46(1), 13–7 (2010).
   PubMed Web of Science ®Google Scholar
• Yadav VK, Balaji S, Suresh PS et al. Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat. Med.16(3), 308–312 (2010).
   PubMed Web of Science ®Google Scholar
• Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell87(2), 159–170 (1996).
   PubMed Web of Science ®Google Scholar
• Glass DA 2nd, Bialek P, Ahn JD et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev. Cell8(5), 751–764 (2005).
   PubMed Web of Science ®Google Scholar
• Olson EN, Schneider MD. Sizing up the heart: development redux in disease. Genes Dev.17(16), 937–956 (2003).
   Google Scholar
• van Gijn ME, Daemen MJ, Smits JF, Blankesteijn WM. The Wnt-frizzled cascade in cardiovascular disease. Cardiovasc. Res.55(1), 16–24 (2002).
   Google Scholar
• Spencer GJ, Utting JC, Etheridge SL, Arnett TR, Genever PG. Wnt signalling in osteoblasts regulates expression of the receptor activator of NFκB ligand and inhibits osteoclastogenesis in vitro. J. Cell Sci.119(Pt 7), 1283–1296 (2006).
   PubMed Web of Science ®Google Scholar
• Martin TJ, Sims NA. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol. Med.11(2), 76–81 (2005).
   PubMed Web of Science ®Google Scholar
• Frost HM. Bone’s mechanostat: a 2003 update. Anat. Rec. A Discov. Mol. Cell Evol. Biol.275(2), 1081–1101 (2003).
   PubMedGoogle Scholar
• Robling AG, Niziolek PJ, Baldridge LA. Mechanical stimulation of bone in vivo reduces osteocyte expression of SOST/sclerostin. Biol. Chem.283(9), 5866–5875 (2008).
   Google Scholar
• van Bezooijen RL, Papapoulos SE, Hamdy NAT, Lowik CWGM. Principles of Bone Biology (3rd Edition), Academic Press Inc. CA, USA (2008).
   Google Scholar
• Ominsky MS, Vlasseros F, Jolette J et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J. Bone Miner. Res.25(5), 948–959 (2010).
   PubMed Web of Science ®Google Scholar